Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
In 2018, the FDA recognized psilocybin as a "breakthrough therapy" for "treatment-resistant depression," a designation that was supposed to facilitate regulatory approval.
- Simplified Text
-
FDA designated psilocybin a 'breakthrough therapy' in 2018.
- Confidence Score
- 0.900
- UUID
- cf05c324-5853-41fd-857e-0309476ceee3
- Vector Index
- ✗ No vector
- Created
- December 6, 2025 at 12:39 AM (4 months ago)
- Last Updated
- December 6, 2025 at 12:39 AM (4 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
18
claims
🔥
5 months ago
https://reason.com/2025/11/12/the-perils-of-viewing-psilocybin-strictly-as-a-psychiatric-medication
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.